Rise in infections means hepatitis C market is expected to peak at $15.5 billion in 2022

27 August 2013

The hepatitis C market is forecast to increase by a massive 230% in the next nine years, according to research and consulting firm Datamonitor Healthcare, which says the market is expected to peak at $15.5 billion in 2022.

US biotech firm Gilead Sciences’ (Nasdaq: GILD) highly anticipated drug sofosbuvir will be the main contributor to market value as it has demonstrated promising results in clinical trials.

Fierce competition between several big pharma companies including US drugmaker AbbVie (NYSE: ABBV), US health care giant Johnson & Johnson (NYSE: JNJ) and US drug major Bristol-Myers Squibb (NYSE: BMY), will also drive this market growth as they rush to develop improved interferon-free regimens.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK